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Background 
It is unclear if blood transfusion in anemic patients with 
acute coronary syndromes is associated with improved 
survival. 
Objective 
To determine the association between blood transfusion 
and mortality among patients with acute coronary 
syndromes who develop bleeding, anemia, or both during 
their hospital course. 
Methods 
Design: Retrospective cohort analysis of prospectively 
collected clinical trial data. 
Setting and Patients: 24,112 patients from three large 
international trials of patients with acute coronary 
syndromes (the GUSTO IIb, PURSUIT, and PARAGON B 
trials). Patients were grouped according to whether they 
received a blood transfusion during the hospitalization. The 
association between transfusion and outcome was 
assessed using Cox proportional hazards modeling that 
incorporated transfusion as a time-dependent covariate and 
the propensity to receive blood, and a landmark analysis. 
Outcomes: The primary outcome was 30-day all-cause 
mortality, with a secondary composite endpoint of 30-day 
mortality or myocardial infarction (MI). 
Results 
Of the 24,112 patients, 2401 (10.0%) underwent at least 
one blood transfusion during their hospitalization. Those 
receiving blood were more likely to be older, female, black, 
have lower bodyweight, more comorbid illness, and ST 
segment depression on their initial EKG. Patients who 
underwent transfusion had a significantly higher unadjusted 
rate of 30-day death (8.00% vs. 3.08%; P<.001), MI 
(25.16% vs. 8.16%; P<.001), and death/MI (29.24% vs. 
10.02%; P<.001) as compared with patients who did not 
undergo transfusion.  
Using Cox proportional hazards modeling that incorporated 
transfusion as a time-dependent covariate and adjusted for 
baseline characteristics, bleeding, transfusion propensity, 
and nadir hematocrit, transfusion was associated with an 
increased hazard for 30-day death (adjusted hazard ratio 
[HR], 3.94; 95% confidence interval [CI], 3.26-4.75) and 30-
day death/MI (HR, 2.92; 95% CI, 2.55-3.35). In the 
landmark analysis that included procedures and bleeding 
events, transfusion was associated with a trend toward 
increased mortality. The predicted probability of 30-day 
death was higher with transfusion at nadir hematocrit values 
above 25%. The adjusted odds ratios for 30-day death 
associated with transfusion by nadir hematocrit were: 
hematocrit 20% (OR, 1.59; 95% CI, 0.95-2.66), hematocrit 
25% (OR, 1.13; 95% CI, 0.70-1.82), hematocrit 30% (OR, 
168.64; 95% CI, 7.49-3797.69), and hematocrit 35% (OR, 
291.64; 95% CI, 10.28-8273.85). 
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Conclusion 
Blood transfusion in the setting of acute coronary 
syndromes is associated with higher mortality, and this 
relationship persists after adjustment for other predictive 
factors and timing of events. Given the limitations of post 
hoc analysis of clinical trials data, a randomized trial of 
transfusion strategies is warranted to resolve the disparity in 
results between our study and other observational studies. 
We suggest caution regarding the routine use of blood 
transfusion to maintain arbitrary hematocrit levels in stable 
patients with ischemic heart disease. 
 
Commentary 
Because the myocardium may be adversely affected by 
anemia in the presence of ischemic heart disease, clinicians 
have commonly used blood transfusions to maintain 
hematocrit values in patients with ischemic heart disease. 
The theory underlying this practice is that blood transfusion 
will increase oxygen delivery and improve outcomes in 
these patients. However, there is no definitive evidence to 
support this premise. 
Recently, this practice, and transfusion practices in general, 
have come under increased scrutiny, as researchers have 
grappled with the question of appropriate transfusion 
thresholds and the potential harmful effects of transfusion, 
such as transfusion related lung injury, viral disease 
transmission, and immune suppression. 
Fueling this controversy are a number of recent studies 
examining appropriate transfusion thresholds and target 
hematocrit values among critically ill patients (Table 1). 
Hébert and colleagues found that a restrictive strategy for 
red cell transfusion is at least as safe and possibly safer 
than a more liberal transfusion strategy when applied to a 
general population of ICU patients [2]. The restrictive 
strategy sought to maintain circulating hemoglobin 
concentrations ≥7.0 g/dL whereas the liberal strategy 
sought to maintain hemoglobin concentration ≥10.0 g/dL [2]. 
This study, however, raised concern that critically ill patients 
with cardiovascular disease might not fair well with the 
restrictive strategy. In a subsequent post hoc analysis of this 
trial, the same group found that the restrictive strategy 
generally appears to be safe in most critically ill patients 
with cardiovascular disease, with the possible exception of 
patients with acute myocardial infarction and unstable 
angina [3]. Others studies have supported this finding [4,5]. 
However, Wu and colleagues, in a large observational study 
utilizing 78,974 Medicare records, found that elderly patients 
with acute MI and an admission hematocrit less than 33% 
had lower 30-day mortality with blood transfusion than those 
who did not receive transfusion [6]. 
It is upon this background that we consider the present 
study by Rao and colleagues [1] which examined the 
association between blood transfusion and mortality in 
24,122 patients with acute coronary syndromes enrolled in 
three large international trials (GUSTO IIb [7], PURSUIT [8], 
PARAGON [9]). They found that transfusion was associated 
with an increased hazard for death within a 30-day interval 
and that the odds of death were higher when transfusion 
occurred at hematocrit nadirs >25%. Based on these 
findings, the authors called for a randomized controlled trial 
of transfusion strategies in this patient population and 
recommended caution regarding the routine use of blood 
transfusion to maintain arbitrary hematocrit levels in patients 
with ischemic heart disease who are otherwise stable. 
 
This study has a number of strengths, including a very large 
sample size, prospectively collected data, and the use a 
variety of robust statistical techniques to address potential 
biases, all of which reached the same conclusions. There 
are, however, a number of limitations that deserve 
consideration. First, this was a post hoc analysis of data 
from three clinical trials, none of which were designed to 
address the question of appropriate transfusion thresholds. 
Thus the study is hypothesis generating and not intended to 
prove cause and effect. Second, since transfusion was a 
post-randomization event, indication bias may have 
influenced the results. The authors do a good job of 
addressing this issue, including the use of a transfusion 
propensity score. However, the potential for this bias still 
exists. Third, because of the nature of the data, the authors 
were unable to include in their analyses consideration of the 
age of the blood transfused or if it was leukoreduced, 
characteristics that may influence the physiologic effect of 
transfusion. Finally, it is unclear whether these results can 
be applied to patients with cardiac disease who do not meet 
GUSTO IIb, PURSUIT, or PARAGON entry criteria, such as 
those with cardiovascular disease coincident to critical 
illness. 
Recommendation 
The results of this study justify the need for a multicenter 
clinical trial of different transfusion strategies in patients with 
acute coronary syndromes with mortality as the primary 
endpoint and with consideration of the age of the blood 
transfused and whether it was leukoreduced as important 
covariates. Until the results of such a trial, it remains clear 
that in otherwise stable intensive care unit patients without 
evidence of active bleeding or acute coronary syndromes, 
restrictive red-cell transfusion strategies appear to be safe 
and may lead to improved outcomes. 
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